Nifty Pharma defies market slump as select drugs get US tariff exemption
29 Sept 2026 · Business Standard Mkts
Qualifying speciality medicines from India will be eligible for zero duty, providing some relief to Indian drugmakers with exposure to the US market.
The analysis
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Market context
- This is a market-wide development — its reach goes beyond any single stock.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads negative.
In this story
Related coverage
Market wrap: ITC, BSE, HCL Tech, Asian Paints top gainers and losers on Nifty and Sensex on Monday
Stock Market Today LIVE: Sensex Rises 500 Points, Nifty 50 Holds 22,700; India VIX Leaps 7%; Trent Rallies 12%
Last line of defence! How 7 Nifty stocks survived the market’s two-month bloodbath
Divi's Labs, TVS Motor could replace Max Healthcare, HDFC Life in Nifty 2027 index review